Cencora Inc. logo

Cencora Inc. (COR)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
339. 66
+2.03
+0.6%
$
71.45B Market Cap
- P/E Ratio
2.2% Div Yield
885,952 Volume
- Eps
$ 337.63
Previous Close
Day Range
336.37 341.18
Year Range
223.92 377.54
Want to track COR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days
Why Cencora (COR) is a Top Growth Stock for the Long-Term

Why Cencora (COR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks | 1 year ago
Here's Why Cencora (COR) is a Strong Growth Stock

Here's Why Cencora (COR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?

Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?

Cencora (COR) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Here's Why Cencora (COR) is a Strong Value Stock

Here's Why Cencora (COR) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Is Walgreens Ready To Rebound?

Is Walgreens Ready To Rebound?

Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments.

Seekingalpha | 1 year ago
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Zacks | 1 year ago
Why Cencora (COR) is a Top Growth Stock for the Long-Term

Why Cencora (COR) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks | 1 year ago
Here's Why Cencora (COR) is a Strong Momentum Stock

Here's Why Cencora (COR) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Why Cencora (COR) is a Top Value Stock for the Long-Term

Why Cencora (COR) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 1 year ago
Loading...
Load More